ArticleInternational journal of molecular sciences2023
Hylin-a1: A Pan-Inhibitor against Emerging and Re-Emerging Respiratory Viruses.
Article in International journal of molecular sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 9 citations in OpenAlex.
- Measles: A Narrative Review of Current Therapeutic Options and Implications for the Future.Viruses · 2026Review
- Ranalexin-1G: A Promising Antimicrobial Peptide Targeting Virulence and Host-Pathogen Interactions inAntibiotics (Basel, Switzerland) · 2026Article
- Identification and Optimization of a Truncated Hs-1-Derived Antimicrobial Peptide for Enhanced Broad-Spectrum Antiviral Activity.ChemMedChem · 2026Article
- Combining receptor engineering and intracellular gelation for cell-based antiviral therapy against coxsackievirus B3.Journal of nanobiotechnology · 2026Article
- Compost Tea as a Natural Bioactive Solution: Unlocking the Antimicrobial and Antiviral Potential of Bell Pepper and Citrus Wastes.Environmental microbiology reports · 2026Article
- Determinants of success and failure of antibody-based strategies against respiratory viruses: insights from RSV and SARS-CoV-2.Frontiers in immunology · 2026Review
- Inactivation of Respiratory Syncytial Virus by Ozone Generated via Dielectric Barrier Discharge Technology with Decrease in Intact Viral Surface Protein.Microorganisms · 2025Article
- Exploring the Antimicrobial and Antiviral Properties of Cryptic Peptides from Human Fibrinogen.International journal of molecular sciences · 2025Article
- The Therapeutic Potential of Antimicrobial Peptides Isolated from the Skin Secretions of Anurans of the GenusToxins · 2025Review
- Frog Skin Peptides Hylin-a1, AR-23, and RV-23: Promising Tools Against Carbapenem-ResistantAntibiotics (Basel, Switzerland) · 2025Article
- A Cyclic Peptide Based on Pheasant Cathelicidin Inhibits Influenza A H1N1 Virus Infection.Antibiotics (Basel, Switzerland) · 2024Article
- SARS-CoV-2 Fusion Peptide Conjugated to a Tetravalent Dendrimer Selectively Inhibits Viral Infection.Pharmaceutics · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 1 country.
Funding
Abstract
Pandemic and epidemic outbreaks of respiratory viruses are a challenge for public health and social care system worldwide, leading to high mortality and morbidity among the human populations. In light of the limited efficacy of current vaccines and antiviral drugs against respiratory viral infections and the emergence and re-emergence of new viruses, novel broad-spectrum antiviral drugs are needed for the prevention and treatment of these infections. Antimicrobial peptides with an antiviral effect, also known as AVPs, have already been reported as potent inhibitors of viral infections by affecting different stages of the virus lifecycle. In the present study, we analyzed the activity of the AVP Hylin-a1, secreted by the frog
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.